Physician profile
Christopher Brown
NPI 1518971563
$1,480.96
in general payments reported to CMS, 2019-2025
24 companies · $13.94 in 2025
The $13.94 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $325 · 2021: $36.49 · 2022: $145 · 2024: $79.17 · 2025: $13.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $225.10 | 2019-2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $170.50 | 2019-2021 | |
| Novo Nordisk INC | $155.66 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.72 | 2019-2020 | |
| Pfizer INC. | $117.58 | 2019 | |
| Glaxosmithkline, LLC. | $116.61 | 2019 | |
| Astellas Pharma US INC | $87.58 | 2019-2020 | |
| Amarin Pharma, INC. | $81.73 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $71.04 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $54.82 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $42.19 | 2020 | |
| Amgen INC. | $36.05 | 2019 | |
| Lilly USA, LLC | $28.54 | 2020-2022 | |
| Allergan, INC. | $19.57 | 2019 | |
| Mylan Specialty L.P. | $16.00 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.35 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $14.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.22 | 2019 | |
| Medtronic, INC. | $13.94 | 2025 | Venaseal |
| Circassia INC. | $13.73 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.07 | 2020 | |
| Cranial Technologies, INC | $11.54 | 2020 | |
| Abbvie INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.